AI Meets Longevity: Firefly and Next Health Bet on Controversial Peptides

KENMORE, NY – July 28, 2026 – In the rapidly converging worlds of artificial intelligence and human longevity, a new partnership is placing a significant bet on the future of cognitive health. Firefly Neuroscience, an AI company specializing in brain analytics, has joined forces with Next Health, a purveyor of high-end longevity clinics. Their goal is to build a platform that marries objective brain measurement with personalized peptide therapies, a venture announced just days after a U.S. Food and Drug Administration advisory panel recommended easing access to some of the very peptides at the heart of the initiative.

The collaboration between Firefly (NASDAQ: AIFF) and Next Health aims to create what they term a "precision cognitive health platform." It's a bold move to quantify the notoriously subjective experience of brain function, using hard data to guide therapies that exist in a regulatory gray area. This initiative represents a fascinating intersection of market opportunism, technological advancement, and a shifting regulatory landscape, raising a critical question: is this the blueprint for the future of preventative medicine, or a leap of faith built on unproven science?

A New Blueprint for Brain Health

The core of the partnership is the integration of two distinct but complementary platforms. On one side is Firefly's Evoke System, an FDA 510(k)-cleared technology that uses AI to analyze electroencephalogram (EEG) and event-related potential (ERP) data. Instead of relying on patient questionnaires, the system provides what Firefly CEO Greg Lipschitz calls "objective neurological biomarkers" to create a data-driven picture of an individual's brain function. The company boasts the world's largest standardized EEG/ERP repository, a massive dataset of over 200,000 scans that fuels its AI algorithms.

"As new peptide therapies...continue to capture global attention...we believe combining Firefly's quantitative brain biomarkers with Next Health's clinical expertise has the potential to redefine how cognitive health is measured, personalized, and monitored," Lipschitz stated in the announcement.

On the other side is Next Health, which has carved out a niche in the burgeoning longevity market. Describing itself as the "vanguard of the longevity revolution," the company operates a network of clinics offering everything from biomarker testing and IV drips to regenerative therapies. The partnership allows Next Health to incorporate Firefly's brain mapping into its protocols, offering clients a seemingly objective measure of progress before, during, and after treatment.

"Our comprehensive functional medicine approach to health is data-driven," commented Dr. Darshan Shah, Founder and CEO of Next Health. "Firefly's FDA-cleared brain wave analytics technology complements that by enabling clinicians to objectively measure brain function." The stated ambition is to replace subjective check-ins with quantifiable data, establishing a scalable framework for integrating neurodiagnostics into routine longevity care.

The Regulatory Tightrope

The timing of the announcement is no coincidence. It follows a pivotal, albeit non-binding, recommendation from an FDA Pharmacy Compounding Advisory Committee (PCAC). Late last week, the committee voted to recommend that six peptides, including Epitalon and Semax, be added to the list of bulk drug substances eligible for pharmacy compounding. This would provide a legal, regulated pathway for licensed pharmacies to prepare these substances for individual patients with a prescription.

However, navigating the implications of this vote requires a forensic look at the regulatory process. The committee's recommendation does not constitute FDA approval of the peptides themselves; Epitalon and Semax are not approved for any use. The vote simply suggests they could be legally compounded. Furthermore, the recommendation is not binding. The FDA must still undertake a formal notice-and-comment rulemaking process, which industry observers estimate could take eight to twelve months.

Crucially, the vote was far from a unanimous endorsement. The recommendation for Epitalon (for insomnia) passed by a narrow 7-5 margin, while Semax (for conditions like cerebral ischemia) passed 8-5. During the meetings, FDA career scientists repeatedly voiced objections, citing a significant lack of robust clinical data to assess the compounds' safety and effectiveness. This internal dissent highlights the deep chasm between the growing consumer and clinical demand for these substances and the rigorous standards of evidence demanded by regulators. The partnership is thus launching into a market where the key therapeutic agents remain in a state of regulatory limbo.

The Science and Hype of 'Neuro-Peptides'

At the center of this new venture are the peptides themselves, particularly Epitalon and Semax, which have garnered scientific interest for potential neuroprotective properties. A closer look reveals a landscape of promising but incomplete science. Semax, for instance, was developed in Russia and is approved there for treating conditions like ischemic stroke. However, it remains an unapproved investigational compound in the U.S. and Europe, with much of the supporting research published in Russian-language journals, posing a challenge for independent verification by Western bodies.

Epitalon's case is even more tenuous. The advisory committee recommended it for compounding to treat insomnia, yet FDA staff noted a lack of publications on its efficacy for this use. Some committee members who voted against it cited the compound's "poor characterization" and even noted a "potential risk with carcinogenicity."

These specific examples point to a broader issue within the booming wellness industry. Many peptides are marketed online and in clinics based on preliminary studies or anecdotal evidence, without having undergone the large-scale, randomized clinical trials required for FDA approval. FDA scientists have warned that these substances often lack sufficient data on safety, efficacy, and proper dosing, and that products sold through unregulated channels can contain impurities or incorrect ingredients. By offering these therapies, even under the guise of advanced monitoring, clinics are operating on the very edge of established medicine, a reality the new partnership will have to confront.

The Business of Biomarkers and Longevity

From a strategic perspective, the Firefly-Next Health alliance is a shrewd move to define and capture an emerging market. For Firefly, a venture-stage company with minimal revenue and a high R&D burn rate, the partnership provides a crucial clinical testbed and a pathway to commercialization. It allows them to demonstrate the value of their Evoke System in a real-world setting, generating data and case studies that could drive wider adoption.

For Next Health, the collaboration adds a layer of high-tech, scientific legitimacy to its suite of premium services. In a crowded wellness market, the ability to offer "objective brain mapping" is a powerful differentiator, appealing to a data-savvy clientele willing to pay for proactive, personalized health optimization. This synergy could create a defensible moat, where advanced diagnostics are used to validate and upsell cutting-edge, high-margin therapies.

Yet this model also raises questions of accessibility and equity. The convergence of AI diagnostics and boutique peptide protocols is creating a new tier of 'precision cognitive health' that will likely be accessible only to the affluent. As these technologies advance, they risk widening the gap in health outcomes, creating a world where optimal brain function becomes another luxury good.

The collaboration between Firefly Neuroscience and Next Health is building a sophisticated framework to measure and manage cognitive health, placing objective data at the forefront of the longevity movement. It is a bold vision for a future that is not quite here, one where these therapies are not only measurable but also proven safe, effective, and accessible. The success of this venture will ultimately depend on whether the treatments being measured can emerge from the regulatory shadows and withstand the full scrutiny of science.